Anthem Biosciences IPO: The Bengaluru-based firm, Anthem Biosciences, has secured Rs 1,016 crore from anchor traders forward of its upcoming Preliminary Public Providing (IPO), which opens for public subscription on July 14.
In response to the BSE web site, the corporate has allotted 1.78 crore fairness shares to 60 anchor traders at Rs 570 per share, which is the higher finish of the IPO value band.
Anthem Biosciences anchor ebook checklist
The anchor ebook noticed participation from a number of distinguished world and home institutional traders. Right here is the checklist:
- Abu Dhabi Funding Authority
- Authorities Pension Fund International
- Eastspring Investments
- Amundi Funds
- PineBridge International Funds
- Société Générale
- HDFC MF
- ICICI Prudential MF
- Axis MF
- UTI MF
- Quant MF
- Motilal Oswal MF
Anthem Biosciences IPO: Value band, lot measurement, key particulars
This situation is a proposal on the market (OFS) by the corporate’s promoters, traders and different personnel materials. Which means that the corporate won’t get any profit from this situation and it will likely be purely a wide range of recommendation. Nevertheless, info like lot measurement and value band has not been disclosed but.
Value band, lot measurement
The corporate has fastened the value band between Rs 540 and Rs 570 per share. Buyers can apply for 26 shares in a single lot and multiples tons.
Monetary efficiency
The corporate reported income of Rs 1,844 crore in FY25, a 30 per cent year-on-year improve in comparison with Rs 1,419 crore in FY24. Whereas its revenue after tax (PAT) rose by 23 per cent to Rs 451 crore throughout the identical interval.
Listed opponents
The corporate has a number of listed business friends, a few of that are leaders within the sector, together with Sai Life Sciences Restricted, Syngene Worldwide, Suven Life Sciences and Divi’s Laboratories.
BRLMs, registrar particulars
JM Monetary, Citigroup International Markets India, JP Morgan India, and Nomura Monetary Advisory and Securities (India) are performing because the book-running lead managers for the IPO. The corporate has appointed Kfin Applied sciences Restricted as registrar for the problems.
About Anthem Bioscience do?
Based in 2006, Anthem Biosciences is a Contract Analysis, Improvement, and Manufacturing Organisation (CRDMO) centered on innovation and know-how. The corporate operates throughout all the pharmaceutical worth chain, together with drug discovery, growth, and manufacturing. It additionally produces and markets complicated fermentation-based Lively Pharmaceutical Substances (APIs) resembling probiotics, enzymes, peptides, dietary actives, vitamin analogues, and biosimilars.